

Disclosure of Value Transfers

Methodological Note

| | |
|---|--|
| Country | Lithuania, Latvia, Estonia |
| Entity Name | Fresenius Kabi Baltics UAB |
| Legal Basis for Disclosure | <p>In general:</p> <ul style="list-style-type: none"> - Medicines for Europe Code of Conduct 2020, published February 2021 <p>Locally:</p> <ul style="list-style-type: none"> - Lithuania: Code of Ethics for Pharmaceutical Marketing. 2020 edition. Adopted by IFPA on 18/06/2020, VGA on 25/06/2020. Order of the Ministry of Health no. V-1537, 23/06/2020; - Estonia: Medicinal Products Act. 2005 edition. Clause 83. General requirements for advertising of medicinal products; - Latvia: Cabinet rules nr. 378, adopted on 17/05/2011, updated 09/09/2021. |
| Reporting Period | 2021 |
| Currency of disclosed values | <p>All values are disclosed in</p> <p><input checked="" type="checkbox"/> EUR</p> <p><input type="checkbox"/> [local currency, if required]</p> |
| Scope of disclosure | The disclosure covers all interactions with HCPs, HCOs and Patient Organizations medicines related to all prescription-only medicinal products (generic, original or biosimilar). Interactions related to medical devices or enteral nutrition products are not disclosed. |
| Value identification and Recognition | All values disclosed are based on value transfers actually made to the respective category that such value transfer has been made to a specific recipient as booked in the respective reporting period (educational grants are disclosed based on the reporting period of the event/congress). |
| Multi-Year Contracts | Value transfers under multiyear contracts are part of the disclosed data to the extent that actual value transfers have been made in the respective reporting period. |
| Data disclosed for | <p>All values are disclosed for</p> <p><input type="checkbox"/> Recipients which have been engaged by entity</p> <p><input checked="" type="checkbox"/> Recipients which have their residence in the country (e.g. EFPIA and Medicines for Europe)</p> |

Disclosure of Value Transfers

| | |
|-----------------------------|---|
| VAT and other taxes | All amounts are disclosed include VAT or similar service taxes, where such apply on the transaction, except for Company Organised Meetings/Site Visits, which are disclosed VAT excluded. |
| Disclosure location: | <ul style="list-style-type: none"> - Lithuania, Latvia, Estonia (MfE disclosure): https://www.fresenius-kabi.com/company/transparency-initiative - Lithuania (State Agency of Medicines): https://www.vvkt.lt/index.php?3523782702 - Latvia (State Agency of Medicines): https://www.vi.gov.lv/lv/pazinojums-par-biedribam-nodibinajumiem-un-arstniecibas-iestadem-sniegto-materialo-vai-cita-veida-atbalstu-0 |

Disclosure of Value Transfers

| | |
|--|--|
| Value category: “Meetings, educational support and site visits of HCPs” | <p>The company discloses value transfers in this category as per Option 2 of the MfE Transparency Requirements:</p> <p>Aggregate total amount of support provided to Healthcare Professionals per individual conference or meeting as follows:</p> <ul style="list-style-type: none"> • Sponsorship for attending a third party organised congress (as per section 6.1): <ul style="list-style-type: none"> - name of congress, - aggregated amount spent for the congress, including the - number of Healthcare Professionals financially supported to attend • Site visits (as per section 6.3): aggregated amount spent, including the number of Healthcare Professionals financially supported to attend. • Company organised meeting: aggregated amount spent, including the number of Healthcare Professionals financially supported to attend. |
| Other Remarks | <p>For value categories related to HCPs, aggregate values have been disclosed where the consent of a multiple number of HCP could not be obtained.</p> <p>Fees paid in connection with research & development activities or market research have not been disclosed.</p> |
